News >

Eryaspase May Provide Second-Line Option in Pancreatic Cancer

Angelica Welch
Published: Monday, Dec 17, 2018

Pascal Hammel, MD, PhD

Pascal Hammel, MD, PhD
An unmet need exists in the second-line treatment of patients with pancreatic adenocarcinoma, explained Pascal Hammel, MD, PhD. To address this, clinical trials are focusing on this setting, such as the TRYbeCA-1 study (NCT03665441) of the L-asparaginase-based therapy eryaspase (Graspa).

, Hammel, a gastroenterologist, oncologist, Hôpital Beaujon, Clichy France, discussed the potential for eryaspase, and the future direction of the pancreatic cancer landscape.

OncLive: Could you provide some background on the data seen with eryaspase?

Hammel: In 2017, we presented the [phase IIb] results of the TRYbeCA-1 study testing eryaspase in patients with pancreatic cancer in the second line following progression on FOLFIRINOX or gemcitabine/nab-paclitaxel (Abraxane)-based chemotherapy. The treatment was well supported. Patients were selected, as only about 50% of patients with pancreatic cancer are able to receive second-line therapy after tumor progression. Both progression-free and overall survival was significantly increased in this phase II trial. We hypothesized that having low asparaginase center activity was predictive of good activity, but that was not the case. Even the group with high asparaginase center activity had good tumor control using eryaspase.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication